Eledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial
Go back to Eledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial| (NASDAQ: ELDN) | Delayed: 2.62 -0.03 (1.13%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.65 | 52 Week High | $ | |||
| Open | $2.67 | 52 Week Low | $ | |||
| Day High | $2.68 | P/E | N/A | |||
| Day Low | $2.57 | EPS | $ | |||
| Volume | 828,838 | |||||
